Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.
Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.
Stem Cell Res Ther. 2017 Oct 3;8(1):218. doi: 10.1186/s13287-017-0639-6.
The dog represents an excellent large animal model for translational cell-based studies. Importantly, the properties of canine multipotent stromal cells (cMSCs) and the ideal tissue source for specific translational studies have yet to be established. The aim of this study was to characterize cMSCs derived from synovium, bone marrow, and adipose tissue using a donor-matched study design and a comprehensive series of in-vitro characterization, differentiation, and immunomodulation assays.
Canine MSCs were isolated from five dogs with cranial cruciate ligament rupture. All 15 cMSC preparations were evaluated using colony forming unit (CFU) assays, flow cytometry analysis, RT-PCR for pluripotency-associated genes, proliferation assays, trilineage differentiation assays, and immunomodulation assays. Data were reported as mean ± standard deviation and compared using repeated-measures analysis of variance and Tukey post-hoc test. Significance was established at p < 0.05.
All tissue samples produced plastic adherent, spindle-shaped preparations of cMSCs. Cells were negative for CD34, CD45, and STRO-1 and positive for CD9, CD44, and CD90, whereas the degree to which cells were positive for CD105 was variable depending on tissue of origin. Cells were positive for the pluripotency-associated genes NANOG, OCT4, and SOX2. Accounting for donor and tissue sources, there were significant differences in CFU potential, rate of proliferation, trilineage differentiation, and immunomodulatory response. Synovium and marrow cMSCs exhibited superior early osteogenic activity, but when assessing late-stage osteogenesis no significant differences were detected. Interestingly, bone morphogenic protein-2 (BMP-2) supplementation was necessary for early-stage and late-stage osteogenic differentiation, a finding consistent with other canine studies. Additionally, synovium and adipose cMSCs proliferated more rapidly, displayed higher CFU potential, and formed larger aggregates in chondrogenic assays, although proteoglycan and collagen type II staining were subjectively decreased in adipose pellets as compared to synovial and marrow pellets. Lastly, cMSCs derived from all three tissue sources modulated murine macrophage TNF-α and IL-6 levels in a lipopolysaccharide-stimulated coculture assay.
While cMSCs from synovium, marrow, and adipose tissue share a number of similarities, important differences in proliferation and trilineage differentiation exist and should be considered when selecting cMSCs for translational studies. These results and associated methods will prove useful for future translational studies involving the canine model.
狗是一种优秀的大型动物转化细胞基础研究模型。重要的是,犬多能基质细胞(cMSCs)的特性和特定转化研究的理想组织来源尚未确定。本研究的目的是使用供体匹配的研究设计和一系列全面的体外特征鉴定、分化和免疫调节测定,从滑膜、骨髓和脂肪组织中分离犬 MSC。
从 5 只患有前十字韧带断裂的狗中分离犬 MSC。所有 15 个 cMSC 制剂均使用集落形成单位(CFU)测定、流式细胞术分析、多能相关基因的 RT-PCR、增殖测定、三系分化测定和免疫调节测定进行评估。数据以均值±标准差表示,并使用重复测量方差分析和 Tukey 事后检验进行比较。以 p<0.05 为显著性差异。
所有组织样本均产生了塑料贴壁、梭形的 cMSC 制剂。细胞对 CD34、CD45 和 STRO-1 呈阴性,对 CD9、CD44 和 CD90 呈阳性,而细胞对 CD105 的阳性程度取决于组织来源。细胞对多能相关基因 NANOG、OCT4 和 SOX2 呈阳性。考虑到供体和组织来源,CFU 潜能、增殖率、三系分化和免疫调节反应存在显著差异。滑膜和骨髓 MSC 表现出较好的早期成骨活性,但在评估晚期成骨时,没有发现显著差异。有趣的是,骨形态发生蛋白-2(BMP-2)补充对于早期和晚期成骨分化是必要的,这一发现与其他犬类研究一致。此外,滑膜和脂肪 MSC 增殖更快,在软骨形成测定中形成更大的聚集,CFU 潜能更高,尽管与滑膜和骨髓颗粒相比,脂肪颗粒中的蛋白聚糖和胶原 II 染色主观上减少。最后,来自所有三种组织来源的 cMSCs 在脂多糖刺激的共培养测定中调节了鼠巨噬细胞 TNF-α和 IL-6 水平。
尽管滑膜、骨髓和脂肪组织来源的 cMSCs 具有许多相似之处,但在增殖和三系分化方面存在重要差异,在选择用于转化研究的 cMSCs 时应予以考虑。这些结果和相关方法将对涉及犬模型的未来转化研究非常有用。